This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea (PUNCH CD)

This study has been completed.
Information provided by (Responsible Party):
Rebiotix Inc. Identifier:
First received: August 15, 2013
Last updated: April 24, 2017
Last verified: April 2017
Results First Received: May 28, 2015  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Recurrent Clostridium Difficile Infection
Intervention: Biological: RBX2660 (microbiota suspension)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment was from 07/15/13 to 12/16/13 at 13 medical clinics in the United States. Recruiment was performed by trained investigators and study coordinators.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
RBX2660 (Microbiota Suspension) This was an open-label, non-randomized, non-controlled subjects. All treated subjects received RBX2660 (microbiota suspension).

Participant Flow:   Overall Study
    RBX2660 (Microbiota Suspension)
Withdrawal by Subject                2 
Death                1 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
RBX2660 (Microbiota Suspension) Open-label; all subjects received RBX2660

Baseline Measures
   RBX2660 (Microbiota Suspension) 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
Count of Participants
<=18 years      0   0.0% 
Between 18 and 65 years      13  38.2% 
>=65 years      21  61.8% 
[Units: Years]
Mean (Full Range)
 (26.7 to 89.6) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      23  67.6% 
Male      11  32.4% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
Hispanic or Latino      1   2.9% 
Not Hispanic or Latino      33  97.1% 
Unknown or Not Reported      0   0.0% 
Region of Enrollment 
[Units: Participants]
United States   34 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660   [ Time Frame: 56 days ]

2.  Secondary:   Long-term Safety   [ Time Frame: 6 months ]

3.  Secondary:   Absence of CDAD at 56 Days   [ Time Frame: 56 days ]

4.  Secondary:   Post-treatment Hospitalization Data   [ Time Frame: 6 months ]

5.  Secondary:   Quality of Life   [ Time Frame: 60 days ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Small sample size (n=34) limits extrapolation of results to a larger population.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Mary Kay Sobcinski, Director of Clinical Operations
Organization: Rebiotix
phone: 6519644488

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Rebiotix Inc. Identifier: NCT01925417     History of Changes
Other Study ID Numbers: 2013-001
Study First Received: August 15, 2013
Results First Received: May 28, 2015
Last Updated: April 24, 2017